Diaphragm pacing is used by patients that have issues breathing due to lung injuries of spinal problems. Diaphragm pacing involves implanting four electrodes into your diaphragm muscle and a fifth electrode just below the skin near the other electrodes.

Market Dynamics

Rapid technological advancements in medical devices and increasing number of patients suffering from lungs issues is resulting in demand for diaphragm pacing therapy system which is major factor expected to drive the growth of global diaphragm pacing therapy system market. There is gradual increase in number inpatients in hospitals suffering from lung injuries due to different cause. In 2020, a total of 2,807 hospitalized EVALI cases or deaths have been reported to CDC from all 50 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands). In the US there have been 2,758 cases of VAPI reported from all 50 states. Diaphragm pacing is any advanced system that aids in improving the breathing and gradually lowers the dependence on a mechanical ventilator. Medical device manufacturers are investing high for product development activities and are focused on introduction of innovative solutions this is expected to impact the growth of diaphragm pacing therapy system market.

In 2020, Avery Biomedical Devices a biomedical engineering and medical device company received approval from FDA its next-generation diaphragm pacemaker transmitter.

In 2020, Lungpacer Medical Inc. a medical device manufacturer received approval from FDA for Emergency Use Authorization for the use of the Lungpacer Diaphragm Pacing Therapy System (DPTS) to assist in weaning patients determined by their healthcare provider to be at high risk of weaning failure.

Manufacturers are focused on enhancing the business their approach towards shifting the manufacturing unit to developing countries due to easy availability of raw material and low cost labor. In addition, favorable business policies by the government of emergence economies and players focus on strategic partnership and agreements are factors expected to boost the growth of diaphragm pacing therapy system market. Diaphragm pacing has various benefits such as reduce or eliminate the time you spend using a ventilator or other assisted breathing devices, help you breathe and speak more naturally, and increase your mobility and transportation options which is gaining importance among patients. Rising covid-19 impact across the globe and rising demand for ventilators this is expected to impact the growth of diaphragm pacing therapy system market. More than 100 million Covid-19 cases have now been recorded worldwide and the United States passed 25 million confirmed cases and the largest death toll of over 420,000. Factors such as high cost of devices and stringent government regulations related to product approval are factors expected to hamper the growth of global diaphragm pacing therapy system market. In addition, lack of developed infrastructure for the adoption of advanced devices in developing countries is expected to challenge the growth of diaphragm pacing therapy system market. However, increasing R&D activities by major players for development cost-effective products and players approach towards integration of AI in the medical devices are factors expected to create new opportunities for players operating in the diaphragm pacing therapy system market. In addition, increasing partnership between regional and international players is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global diaphragm pacing therapy system market due to increasing patient pool suffering from lungs problem. Increasing government spending on development of smart cities, focus on improvement of advanced medical devices and introduction of new product products from major players are factors expected to support the growth of diaphragm pacing therapy system regional market.

Spinal injuries cases in the country are increasing and so is the awareness among consumer related to benefits of diaphragm pacing. In addition, increase in demand for patients for alternative to the mechanical ventilator is expected to increasing demand for diaphragm pacing therapy system. These are factors expected to augment the growth of diaphragm pacing therapy system market.

Competitive Landscape      

The global diaphragm pacing therapy system market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market	Global Diaphragm Pacing Therapy System Market
Analysis Period	2016 – 2027
Base Year	2019
Forecast Data	2020 – 2027
Market Stratification	Product Type, Method, Applications and Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Diaphragm Pacing Therapy System Market Segment Analysis, 2019

The global diaphragm pacing therapy system market is segmented into product type, method and applications. The product type segment is bifurcated into external diaphragm pacemaker and diaphragm pacemaker. Among the product type external diaphragm pacemaker is expected to account for major revenue share in the global diaphragm pacing therapy system market. The application segment is divided into spinal cord injury (SCI), amyotrophic lateral sclerosis (ALS) and others. Among application the spinal cord injury (SCI) segment is expected to account for major revenue share in the target segment due to increasing accidents with spinal injuries across the globe and development of advanced product form major players. The players profiled in the report Avery Biomedical Devices, Lungpacer Medical, Inc, Arahelio, Synapse Biomedical, Atrotech, Boehringer Ingelheim, Novartis, AstraZeneca, Respironics, MedImmune, Actelion, Forest, Pearl, Ikaria, Aeris, PneumRx, and Pulmonx.

Market Segmentation

Market By Product Type

External Diaphragm Pacemaker

Diaphragm Pacemaker

Market By Method

Intrathoracic Diaphragm Pacing (IT-DP)

Intraperitoneal Diaphragm Pacing

Market By Application

Spinal Cord Injury (SCI)

Amyotrophic Lateral Sclerosis (ALS)

Others

Market By Region

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT